Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas

被引:111
|
作者
Alò, PL
Visca, P
Trombetta, G
Mangoni, A
Lenti, L
Monaco, S
Botti, C
Serpieri, DE
Di Tondo, U
机构
[1] Univ Rome La Sapienza, Dipartimento Med Sperimentale & Pathol, I-00161 Rome, Italy
[2] Regina Elena Canc Inst, Serv Citodiagnost, Rome, Italy
[3] Regina Elena Canc Inst, Dipartimento Chirurg, Rome, Italy
关键词
fatty acid synthase; breast carcinoma; prognosis;
D O I
10.1177/030089169908500108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background: Many normal and human cancer tissues express fatty acid synthase (FAS), the major enzyme required for endogenous fatty acid biosynthesis. Strong expression of FAS seems to be associated with a poor prognosis. This study examines the strength of FAS and other common markers of relapse in poorly differentiated breast carcinoma. Materials and methods: Fifty-one patients with poorly differentiated ductal infiltrating breast carcinomas were followed up for more than 10 years. Immunohistochemical detection of FAS was associated with morphological features of the tumors, with immunohistochemical expression of c-erbB-2, cathepsin D, estrogen and progesterone receptor status and with DNA ploidy in order to detect a statistical correlation, Results: The chi-square test revealed a correlation between FAS and peritumoral lymphatic vessel invasion (PLVI) (P = 0.001). Univariate analysis showed that FAS was correlated with disease-free survival (DFS) (P=0.0001), Other prognosticators associated with DFS were PLVI (P = 0.002), estrogen (P = 0.008) and progesterone receptor status (P = 0.007), Bivariate analysis showed that FAS was a further prognostic discriminant of DFS within the ER, PgR and PLVI subsets. Discussion: FAS is a reliable prognosticator of recurrence in poorly differentiated early breast carcinomas, Association of FAS with PLVI may be useful to plan a correct follow-up in patients with breast neoplasms.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 50 条
  • [1] Fatty acid synthase predictive's strength in early breast carcinoma patients.
    Alo, PL
    Trombetta, G
    Monaco, S
    Serpieri, DE
    NEW TECHNOLOGIES IN REPRODUCTIVE MEDICINE, NEONATOLOGY AND GYNECOLOGY, 1999, : 281 - 287
  • [2] Fatty acid synthase (FAS) expression in invasive cervical carcinomas
    Ji, C
    Hsu, CY
    Ronnett, BM
    Wu, TC
    Kuhajda, FP
    LABORATORY INVESTIGATION, 2005, 85 : 187A - 187A
  • [3] Fatty acid synthase (FAS) expression in invasive cervical carcinomas
    Ji, H
    Hsu, CY
    Ronnett, BM
    Wu, TC
    Kuhajda, FP
    MODERN PATHOLOGY, 2005, 18 : 187A - 187A
  • [4] Predictive factors for recurrence in poorly differentiated thyroid carcinomas
    Zahan, E. -A.
    Nechifor-Boila, A.
    Piciu, D.
    Borda, A.
    VIRCHOWS ARCHIV, 2019, 475 : S227 - S227
  • [5] Predictive factors of outcome in poorly differentiated thyroid carcinomas
    de la Fouchardiere, Christelle
    Decaussin-Petrucci, Myriam
    Berthiller, Julien
    Descotes, Francoise
    Lopez, Jonathan
    Lifante, Jean-Christophe
    Peix, Jean-Louis
    Giraudet, Anne-Laure
    Delahaye, Armelle
    Masson, Sandrine
    Bournaud-Salinas, Claire
    Chazot, Francoise Borson
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : 40 - 47
  • [6] Expression of fatty acid synthase (FAS) in columnar cell lesions of the breast
    Turashvili, G. A.
    Watson, P. H.
    Gillas, C. B.
    Schaeffer, D. F.
    Jensen, K. C.
    Mongomery, K. D.
    de Rijn, J. M. van
    Aparicio, S. A.
    LABORATORY INVESTIGATION, 2008, 88 : 57A - 57A
  • [7] Expression of fatty acid synthase (FAS) in columnar cell lesions of the breast
    Turashvili, G. A.
    Watson, P. H.
    Gilks, C. B.
    Schaeffer, D. F.
    Jensen, K. C.
    Montgomery, K. D.
    van de Ryn, J. M.
    Aparicio, S. A.
    MODERN PATHOLOGY, 2008, 21 : 57A - 57A
  • [8] Inhibition of fatty acid synthase (FAS) for breast cancer chemoprevention.
    Alli, PM
    Pinn, M
    Jaffe, E
    Kuhajda, F
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1344S - 1344S
  • [9] Regulation of fatty acid synthase (FAS)
    Semenkovich, CF
    PROGRESS IN LIPID RESEARCH, 1997, 36 (01) : 43 - 53
  • [10] Overexpression of fatty acid synthase (FAS) in recurrent, chemoresistant ovarian serous carcinomas and the potential therapeutic role of selective FAS inhibitors
    Ueda, S. M.
    Li, Q.
    Wang, T.
    Kuhajda, F.
    Davidson, B.
    Shih, I.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S16 - S16